{"disease":{"id":"alagille-syndrome","name":"alagille syndrome"},"drugs":{"marketed":[{"drug_id":"maralixibat-hydrochloride","indication_name":"Cholestatic pruritus in Alagille syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livmarli","generic_name":"maralixibat hydrochloride","company_name":"Mirum Pharma Inc","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor","quality_score":57,"revenue":null,"mechanism":"Livmarli works by blocking the ileal sodium/bile acid cotransporter, which reduces the amount of bile acids reabsorbed into the bloodstream."},{"drug_id":"maralixibat-hydrochloride","indication_name":"Cholestatic pruritus in patients with Alagille syndrome (ALGS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livmarli","generic_name":"maralixibat hydrochloride","company_name":"Mirum Pharma Inc","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor","quality_score":57,"revenue":null,"mechanism":"Livmarli works by blocking the ileal sodium/bile acid cotransporter, which reduces the amount of bile acids reabsorbed into the bloodstream."},{"drug_id":"livmarli","indication_name":"Cholestatic pruritus in patients with Alagille syndrome (ALGS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livmarli","company_name":"Mirum Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00571272","title":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)","phase":"","overall_status":"SUSPENDED","enrollment_count":1675,"lead_sponsor_name":"Arbor Research Collaborative for Health","has_results":false},{"nct_id":"NCT02922751","title":"FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)","phase":"","overall_status":"COMPLETED","enrollment_count":552,"lead_sponsor_name":"Arbor Research Collaborative for Health","has_results":false},{"nct_id":"NCT07290257","title":"Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05035030","title":"Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Albireo, an Ipsen Company","has_results":false},{"nct_id":"NCT06193928","title":"Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04674761","title":"Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Albireo","has_results":true},{"nct_id":"NCT07293897","title":"A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02057692","title":"Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02117713","title":"An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02160782","title":"Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04729751","title":"A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02047318","title":"An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05488067","title":"Atorvastatin Therapy on Xanthoma in Alagille Syndrome","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT05543174","title":"A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03082937","title":"An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Albireo","has_results":false},{"nct_id":"NCT04530994","title":"A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}